Track market-moving stories before they get noisy

ANTWERP, Belgium, 8 September 2026, 08:00 a.m. CET – CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMB.TECH” or the “Company”) (NYSE: CMBT, Euronext Brussels: CMBT en Euronext Oslo Børs: CMBTO) invites its shareholders to participate in the Special General Meeting that will be held on Thursday 8 October 2026.

CMB.TECH invites its shareholders to participate in the Special General Meeting that will be held on Thursday 8 October 2026 at 10.30 CET in 2000 Antwerp, De Gerlachekaai 20.

In view of the record date of Thursday 24 September 2026, shareholders may not reposition shares between the Belgian Register and the U.S. Register during the period from Wednesday 23 September 2026 at 8.00 a.m. (Belgian time) until Friday 25 September 2025 at 8.00 a.m. (Belgian time) (“Freeze Period”).

The convening notice and other documents related to this meeting are available on the CMB.TECH website in the investors section under General Meetings.

The agenda and practical formalities for participation in this meeting are described in the convening notice.

Publication Q3 2026 results – 26 November 2026

About CMB.TECH

CMB.TECH (all capitals) is one of the largest listed, diversified and future-proof maritime groups in the world with a combined fleet of about 235 vessels: dry bulk vessels, crude oil tankers, chemical tankers, container vessels and offshore energy vessels. CMB.TECH also offers hydrogen and ammonia fuel to customers, through own production or third-party producers.

CMB.TECH is headquartered in Antwerp, Belgium, and has offices across Europe, Asia and Africa.

CMB.TECH is listed on Euronext Brussels and the NYSE under the ticker symbol “CMBT” and on Euronext Oslo Børs under the ticker symbol “CMBTO”.

More information can be found at https://cmb.tech

Forward-Looking Statements

Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbour protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The Company desires to take advantage of the safe harbour provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbour legislation. The words "believe", "anticipate", "intends", "estimate", "forecast", "project", "plan", "potential", "may", "should", "expect", "pending" and similar expressions identify forward-looking statements.

The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, our management's examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs or projections.

In addition to these important factors, other important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include the failure of counterparties to fully perform their contracts with us, the strength of world economies and currencies, general market conditions, including fluctuations in charter rates and vessel values, changes in demand for tanker vessel capacity, changes in our operating expenses, including bunker prices, dry-docking and insurance costs, the market for our vessels, availability of financing and refinancing, charter counterparty performance, ability to obtain financing and comply with covenants in such financing arrangements, changes in governmental rules and regulations or actions taken by regulatory authorities, potential liability from pending or future litigation, general domestic and international political conditions, potential disruption of shipping routes due to accidents or political events, vessels breakdowns and instances of off-hires and other factors. Please see our filings with the United States Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties.

This information is published in accordance with the requirements of the Continuing Obligations on Euronext Oslo Børs.

Contact

CMB.TECH
Katrien Hennin
Head of Marketing and Communications
+32 499 39 34 70
[email protected]

Joris Daman
Head of Investor Relations
Tel: +32 498 61 71 11
[email protected]

CMBT_PressRelease_SGM

ANTWERP, Belgium, 27 August 2026 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its unaudited financial results today for the second quarter ended 30 June 2026.

HIGHLIGHTS

Financial highlights: Profit for the period of USD 364.4 million in Q2 2026. EBITDA for the same period was USD 552.8 million.CMB.TECH’s contract backlog stable at USD 3.26 billion with the addition of 2 x 2-year CSOV time charters and 1 x 1-year VLCC time charter​Intention to distribute an amount of USD 0.64 per share.  Fleet highlights:

Delivery of 9 newbuilding vessels (Q2 + Q3 to date): Newcastlemaxes: Mineral Latvija, Mineral Magyar, Mineral Eesti, Mineral LietuvaVLCCs: MoriniSuezmaxes: Cap Grace, Cap JosephCSOV: Windcat HaarlemCTV: FRS Windcat 65  CMB.TECH and Fortescue have signed a milestone agreement for the charter of up to 12 ammonia-powered Newcastlemax vessels (210,000 dwt)Previously announced sale of VLCCs Ilma (2012, 314,000 dwt) and VLCC Ingrid (2012, 314,000 dwt). The sale generated a gain of a USD 98.2 million in Q2 2026.Previously announced sale of Suezmax Sienna (2007 - 150,205 dwt). The sale generated a gain of USD 29.2 million.Sale of VLCC Donoussa (2016, 299,999 dwt). This sale will generate a gain of approximately 74.3 million USD in Q4 2026, based on the net sale price and book values.Sale of three Suezmaxes, Brest (2023, 156,851 dwt), Brugge (2023, 156,851 dwt) and Bristol (2024, 156,851 dwt). These sales will generate a gain of approximately 100.2 million USD in Q3 2026 and 56.9 million USD in Q4 2026, based on the net sale price and book values. For the second quarter of 2026, the company realised a net profit of USD 364.4 million or USD 1.26 per share (second quarter 2025: a net profit of 7.8 USD million or USD 0.04 per share attributable to the owners of the Company). EBITDA (a non-IFRS measure) for the same period was USD 552.8 million (second quarter 2025: USD 224.1 million).

“CMB.TECH achieved excellent results in the second quarter of 2026, supported by continued strength in tanker and dry bulk markets. We continue to make hay while the sun shines, building on the important strategic decisions taken over the past three years: diversifying beyond tankers, acquiring Golden Ocean and investing in a future-proof newbuilding programme.

While uncertainties remain around global trade, geopolitical tensions and the tanker orderbook, CMB.TECH is well positioned to navigate changing market conditions and to continue creating long-term value.” - Alexander Saverys, CEO CMB.TECH.

Key figures

             The most important key figures (unaudited) are:                       (in thousands of USD)   Second Quarter 2026 Second Quarter 2025 YTD 2026 YTD 2025              Revenue          703,943         387,808         1,223,573         622,852          Other operating income          16,724         13,021         37,055         20,155                      Raw materials and consumables          (594)         (2,319)         (2,003)         (5,128)          Voyage expenses and commissions          (144,349)         (81,338)         (249,168)         (123,742)          Vessel operating expenses          (125,469)         (113,644)         (252,956)         (175,473)          Charter hire expenses          (3,756)         (1,307)         (3,974)         (1,620)          General and administrative expenses          (30,771)         (33,548)         (58,558)         (56,395)          Net gain (loss) on disposal of tangible assets          127,517         57,340         394,871         103,791          Depreciation and amortisation          (111,425)         (108,698)         (217,996)         (164,369)          Impairment reversals/(losses)          140         (3,573)         729         (3,573)                      Net finance expenses          (76,172)         (118,225)         (157,869)         (182,440)          Share of profit (loss) of equity accounted investees          9,399         1,622         21,495         1,571          Profit (loss) before income tax          365,187         (2,861)         735,199         35,629                      Income tax benefit (expense)          (807)         (4,723)         (1,985)         (2,840)  Profit (loss) for the period          364,380         (7,584)         733,214         32,789                      Attributable to:            Owners of the Company          364,380         7,768         733,214         51,766           Non-controlling interest          —         (15,352)         —         (18,977)                                             Earnings per share:                     (in USD per share) Second Quarter 2026 Second Quarter 2025 YTD 2026 YTD 2025             Weighted average number of shares (basic) *         290,169,769         194,216,835                 290,169,769         194,216,835          Basic earnings per share         1.26         0.04                 2.53         0.27                                The number of shares issued on 30 June 2026 is 315,977,647. However, the number of shares excluding the owned shares held by CMB.TECH at 30 June 2026 is 290,169,769.             EBITDA reconciliation (unaudited):                     (in thousands of USD) Second Quarter 2026 Second Quarter 2025 YTD 2026 YTD 2025             Profit (loss) for the period         364,380         (7,584)                 733,214         32,789          + Net finance expenses         76,172         118,225                 157,869         182,440          + Depreciation and amortisation         111,425         108,698                 217,996         164,369          + Income tax expense (benefit)         807         4,723                 1,985         2,840          EBITDA (unaudited)         552,784         224,062                 1,111,064         382,438                                 EBITDA per share:                       (in USD per share)  Second Quarter 2026 Second Quarter 2025 YTD 2026 YTD 2025              Weighted average number of shares (basic)          290,169,769         194,216,835                 290,169,769         194,216,835          EBITDA          1.91         1.15                 3.83         1.97                                  All figures, except for EBITDA and EBITDA per share, have been prepared under IFRS as adopted by the EU (International Financial Reporting Standards) and have not been audited nor reviewed by the statutory auditor.

Intention of distribution

The Supervisory Board proposes a total distribution of USD 0.64 per share, consisting of (i) an intermediary dividend of USD 0.21 per share (subject to 30% withholding tax, to the extent no exemption or reduction applies) and (ii) a payment of USD 0.43 per share out of the available share premium (which is exempt from withholding tax) (the “Distribution”). 

The Distribution is subject to the completion of the relevant corporate procedures prescribed by the Belgian Companies and Associations Code (Wetboek van vennootschappen en verenigingen / Code des sociétés et des associations) and, in particular, the approval of the Distribution by the Special Shareholders’ Meeting of CMB.TECH, which will be convened later this year (the “Shareholders’ Meeting”). 

CMB.TECH will provide further information on the payment date (expected in October), record date and other practical modalities of the Distribution once the Distribution is effectively approved by the Shareholders Meeting, in accordance with applicable regulations. 

TCE

The average daily time charter equivalent rates (TCE, a non IFRS-measure) can be summarised as follows:

 Q2 2026Q2 2025Quarter-to-Date Q3 2026USD/dayUSD/dayUSD/dayFixed %DRY BULK VESSELSNewcastlemax average spot rate(1)46,19823,08143,09685%Capesize average spot rate(1)39,998 32,87377%Capesize average time charter rate32,102   Panamax/Kamsarmax average spot rate(1)20,226 19,13784%Panamax/Kamsarmax average time charter rate13,765   TANKERSVLCC average spot rate (1)126,79044,981125,40483%VLCC average time charter rate(3)78,43446,094  Suezmax average spot rate(1) (3)123,40540,160117,57973%Suezmax average time charter rate34,72633,023  CONTAINER VESSELSAverage time charter rate29,58929,378  CHEMICAL TANKERSAverage spot rate(1) (2)22,02122,41122,350NAAverage time charter rate19,65819,306  OFFSHORE ENERGYCSOV Average time charter rate64,451 50,51165%CTV Average time charter rate3,5653,1463,76598% 1) Reporting load-to-discharge for TCEs, in line with IFRS 15, net of commission. Revenue days are the aggregate number of calendar days in the period in which the vessels are owned by the Company or chartered by the Company less days on which a vessel is off hire or repositioning days in connection with sale
(2) CMB.TECH owned ships in Stolt Pool (excluding technical off hire days)
(3) Including profit share where applicable

CMB.TECH FLEET DEVELOPMENTS

Commercial contracts

CMB.TECH’s contract backlog stable at USD 3.26 billion with the addition of 2 x 2-year CSOV time charters and 1 x 1-year VLCC time charter​CMB.TECH and Fortescue have signed a milestone agreement for the charter of up to 12 ammonia-powered Newcastlemax vessels (210,000 dwt) Sales

Following vessels were delivered to their new owners in Q2 2026 - generating a total gain of approximately USD 127.4 million:

Two VLCCs: Ilma (2012, 314,000 dwt) and Ingrid (2012, 314,000 dwt) - gain of approximately USD 98.2 million in Q2 2026, based on the net sales price and book values. One Suezmax Sienna (2007, 150,205 dwt). The sale generated a gain of USD 29.2 million and was delivered in the second quarter of 2026. Following vessels will be delivered to their new owners in Q3 2026:

Two Suezmaxes: Brest (2023, 156,851 dwt) and Brugge (2023, 156,851 dwt). This sale will generate a gain of approximately 100.2 million USD in Q3 2026, based on the net sale price and book values. Following vessels will be delivered to their new owners in Q4 2026:

VLCC Donoussa (2016, 299,999 dwt). This sale will generate a gain of approximately 74.3 million USD in Q4 2026, based on the net sale price and book values.Suezmax Bristol (2024, 156,851 dwt). This sale will generate a gain of approximately 56.9 million USD in Q4 2026​, based on the net sale price and book values. Newbuilding deliveries

Delivery dateType of vesselName8 April 2026SuezmaxCap Grace (2026, 156,000 dwt)27 April 2026SuezmaxCap Joseph (2026, 156,000 dwt)4 May 2026CSOVWindcat Haarlem (2026)11 May 2026NewcastlemaxMineral Latvija (2026, 210,000 dwt)28 May 2026NewcastlemaxMineral Eesti (2026, 210,000 dwt)8 June 2026NewcastlemaxMineral Magyar (2026, 210,000 dwt)10 June 2026VLCCMorini (2026, 319,000 dwt)29 June 2026NewcastlemaxMineral Lietuva (2026, 210,000 dwt)14 July 2026CTVFRS Windcat 65 MARKET & OUTLOOK

Bocimar – Dry Bulk Market1

Dry bulk markets entered 2026 with strong momentum, with the Baltic Dry Index averaging materially higher year-on-year in Q2 and spot earnings across major dry-bulk vessel classes trending well above seasonal norms. Capesize C5TC (BCI-182) time charter equivalent (TCE) earnings averaged USD 39,806 per day during Q2 2026, compared to a 10-year historical average of USD 22,926 per day2. Average sector earnings in the second quarter were supported by robust major bulk volumes, firm minor bulk activity, and generally tighter effective fleet supply. Continuing on a strong Q2, the Capesize C5TC (BCI-182) average for July stands at 38,646 USD/day, 13,671 USD/day higher compared to July 2025 (BCI-182 recalculated basis) – and increased further in August up to 46,201 USD/day.

Iron ore trade remained a key pillar of dry bulk demand during the second quarter of 2026. Overall global iron ore seaborne transportation increased by 0.9% between Q2 2025 and Q2 2026, and by 12.2% between Q1 2026 and Q2 2026. China imported 316.4 million tonnes of iron ore in Q2, up 0.6% year-on-year, bringing first-half imports to 637.4 million tonnes, an increase of 5.1% compared to the same period last year. Although Chinese steel production remains under pressure, domestic iron ore production declined by 7% year-on-year to 466.9 million tonnes during the first half of the year, increasing reliance on higher-quality imported ores.

Looking ahead, continued strength in seaborne iron ore trade is supported by the production and shipment guidance of the major iron ore miners and the ongoing ramp-up of the Simandou project. Iron ore export volumes historically strengthen in the second half of the year, with weekly shipments typically increasing by approximately 7.7% from week 27 (start H2) through year-end compared with the first H1 weeks. Vale maintained its 2026 production guidance of 335-345 million tonnes, implying second-half production growth ranging from -2.0% to +3.4% year-on-year depending on the outcome within the guidance range. Fortescue's FY27 shipment guidance of 197-207 million tonnes points to broadly stable export volumes, while BHP's FY27 production guidance midpoint of 266 million tonnes is also broadly unchanged year-on-year. Rio Tinto's unchanged 2026 guidance implies a meaningful increase in second-half Pilbara shipments compared with the first half, while the gradual ramp-up of Simandou provides additional support to tonne-mile demand. Although initial Simandou volumes remain modest, the Guinea-China trade route is more than three times longer than the traditional Australia-China iron ore trade, creating a disproportionately positive impact on vessel demand and fleet utilisation.

Coal emerged as one of the strongest contributors to dry bulk demand during the quarter. Global seaborne coal transportation reached 276 million tonnes in Q2 2026, increasing by 11.8% between Q2 2025 and Q2 2026, and by 15.1% between Q1 2026 and Q2 2026. Seaborne coal transportation accelerated following the disruption of Middle East energy flows, as higher LNG prices supported coal consumption in several importing countries (mainly Europe, Japan, South Korea, and Taiwan). While coal demand remains closely linked to weather patterns and energy markets, current market fundamentals suggest continued support for seaborne coal demand through Q3 and potentially into Q4.

In addition, Chinese domestic coal production was constrained by enhanced safety inspections following a major mining accident, while rising summer temperatures and strong power demand increased import requirements. China’s electricity consumption rose 5.3% year-on-year during the first half of 2026, with repeated records in peak electricity loads. Demand for both thermal and metallurgical coal strengthened, with Australian coal shipments to China nearing multi-year highs in July 2026.

Bauxite continues to be one of the strongest growth commodities in the dry bulk market. Despite recurring rumours regarding export restrictions in Guinea, volumes have remained robust and largely uninterrupted. Global seaborne bauxite transportation reached 60.6 million tonnes in Q2 2026, increasing by 4.6% between Q2 2025 and Q2 2026, and decreasing -13.9% between Q1 2026 and Q2 2026. As per the regular seasonal pattern, volumes eased during the peak rainy season (summer period). Volumes are expected to recover as weather conditions improve by Q3/Q4. As a result, bauxite is expected to remain an important source of tonne-mile demand during the second half of the year and continues to play an increasingly important role in global dry bulk trade growth.

Grain trade also provided solid support to dry bulk markets during the quarter. Global seaborne grains transportation reached 70.0 million tonnes in Q2 2026, increasing by 8.6% between Q2 2025 and Q2 2026, and by 0.7% between Q1 2026 and Q2 2026. Brazil remained the dominant supplier (128 million tonnes for H1 or 27.8% market share), benefiting from a large crop and competitive pricing, while the United States (87 million tonnes for H1 or 18.9% market share) has gradually regained market share and is expected to increase exports during the upcoming harvest season. The competition between Brazilian and US exports to China is supportive for tonne-mile demand and is expected to sustain healthy vessel utilisation during the second half of 2026 as seasonal trade flows shift between origins.

Weather developments remain an important factor for dry bulk markets. The National Oceanic and Atmospheric Administration (NOAA) officially declared El Niño in June 2026, with a 97% chance it will persist through early spring 2027. Historically, major El Niño events have disrupted agricultural production, altered commodity trade patterns, affected hydropower generation and increased coal demand in several regions. Early impacts have already been observed in Asia through stronger electricity demand and changing energy consumption patterns. While full weather effects always remain uncertain, a prolonged and severe El Niño event could support additional commodity trade flows and increase volatility across several dry bulk cargo segments through late 2026 and into 2027.

There have been some reports about a pick-up in demand for coal-fired power generation in Japan and the need to replace the drop in hydro generation as 2Q26 El Niño weather patterns pressured hydropower output. This is happening on the backdrop of reduced gas-fired output on gas-to-coal switching as the Hormuz conflict continues to keep LNG prices high. Coal discharges to Japan have been up 4% year-over-year, with thermal coal discharges increasing to 53.9 million tonnes in H1 2026, whilst coking coal discharges remained largely flat.

Bocimar has 40 (+6NB) Newcastlemaxes on the water (average age 3.2y), 37 Capesize vessels on the water (average age 11.2y), and 30 Kamsarmax/Panamax vessels on the water (average age 7.4y).

Bocimar performance highlights:

 TCE Q2 2026QTD Q3 2026Newcastlemax SPOT46,19843,096 (85% fixed)Capesize SPOT39,99832,873 (77% fixed)Kamsarmax/Panamax SPOT20,22619,137 (84% fixed) Euronav – Tanker Markets3

Crude tanker markets experienced exceptional volatility during Q2 2026, primarily driven by escalating geopolitical tensions in the Middle East and the disruption of shipping flows through the Strait of Hormuz (SOH) and the Bab el-Mandeb Strait. Transit volumes through the Strait of Hormuz declined materially beginning of March from on average 120 daily crossing to on average 10 daily crossings between March and mid-June. On 17 June, the presidents of the US and Iran signed the Islamabad Memorandum, that formalized the process of ending the war and established a 60-day period to negotiate the final terms of a deal, enabling a temporary ceasefire. This resulted in a rapid recovery of Strait of Hormuz traffic with on average more than 40 daily SOH crossing. Geopolitical tensions escalated again in early July, and the ceasefire ended on July 7th. As a resultant, daily crossing dropped again towards on average 20 daily crossings. Both sides have since treated the Islamabad MoU as void, the US blockade is reported as still operating, Bab el-Mandeb transits have fallen to multi-month lows on renewed Houthi activity – increasing the likelihood of Red Sea escalation risk.

The resulting scramble for available tonnage led to sharp spikes in spot freight rates across key benchmark routes. Against this backdrop, VLCC time charter equivalent (TCE) earnings averaged USD 140,029 per day in Q2 2026, compared to a Q2 10-year historical average of USD 30,198 per day. Suezmax earnings followed a similar trajectory, with Q2 2026 TCE averaging USD 146,567 per day versus a Q2 10-year average of USD 30,946 per day.

The disruption also led to a widespread reconfiguration of global crude trade flows. Importing nations increasingly sourced barrels from alternative regions, while exporters outside the Middle East, including the United States, Brazil, Kazakhstan and Venezuela, increased shipments to partially offset lost Arabian Gulf volumes. Longer voyage distances and a more complex trading environment temporarily supported tonne-mile demand and fleet utilisation. At the same time, elevated uncertainty around regional security conditions delayed a full return to normal trading patterns and encouraged charterers to secure tonnage well in advance. However, despite the strong freight market performance, several underlying market indicators suggest a more cautious medium-term outlook.

During the recent disruption around the Strait of Hormuz, Chinese crude imports declined sharply, as buyers drew on substantial inventories rather than competing aggressively for replacement barrels. China’s strategic and commercial crude inventories were estimated at around 1.25 billion barrels at the end of 2025, providing a significant buffer against supply shocks and elevated prices. This inventory position enables China to be a price-sensitive and tactical buyer of seaborne crude oil. Rather than acting as a passive source of demand, China can increasingly time purchases depending on price levels, refinery margins and geopolitical risk. This helped cushion the immediate impact of the Iran-related disruption on global oil prices, but it also makes future crude import demand more dependent on inventory cycles and opportunistic restocking. For crude tanker demand, the medium-term outlook therefore depends not only on underlying oil consumption, but also on the pace at which China rebuilds inventories. Once the oil prices settle again, restocking in China (and other Asian economies) could support seaborne crude flows and tonne-mile demand. At the same time, Chinese refiners remain cautious amid weakened domestic fuel demand, high product inventories and continued fuel substitution through continuously increasing electrification and growth in the renewables sector, and by oil to coal switching. China’s high EV penetration has allowed some switching to driving on electricity rather than gasoline: gasoline consumption was 23% lower and EV charging volume 60% higher year over year in April and May.

Despite recent geopolitical disruptions, the underlying global oil market continues to face the prospect of a significant supply surplus. To date, there has been no sustained damage to major energy production infrastructure, supporting expectations that global oil supply can recover relatively quickly once tensions ease. In such a scenario, depleted inventories would likely be replenished, and trade flows progressively normalise. While recent events have temporarily supported tanker demand through longer haul voyages, market fundamentals suggest that any prolonged normalisation of Middle-East trade flows could see tanker demand gradually return towards underlying historic levels. Looking ahead, the ever-growing crude tanker orderbook remains an important consideration for the medium-term market balance and earnings outlook. Over the past months, the orderbook experienced the strongest period of newbuilding investment in the last 50 years (620 VLCCs and Suezmax units on order).

Euronav has 2 FSOs (average age 24y), 4 (+1NB) VLCCs (average age <1.0y) and 15 Suezmaxes (average age 8.1y) on the water4.

Euronav performance highlights:

 TCE Q2 2026QTD Q3 2026VLCC SPOT126,790 USD/day125,404 (83% fixed)SUEZMAX SPOT123,405 USD/day117,579 (73% fixed)  Delphis – Container Markets5

Container markets strengthened during the second quarter of 2026, supported by resilient cargo demand, continued disruption in Middle Eastern trade lanes and elevated congestion across key transhipment hubs. The closure of the Strait of Hormuz and the delayed return of Red Sea transits extended voyage distances, tightened effective vessel supply and supported both freight and charter markets. As a result, time charter rates reached their highest levels outside the post-pandemic period, while freight rates increased materially throughout the quarter, particularly on the Asia-Europe and Transpacific trades. Global trade volumes remained resilient despite regional disruptions, supported by robust demand on the main East-West routes, Intra-Asia and North-South trades.

Peak season demand, ongoing supply chain adjustments and a gradual rather than immediate normalisation of Middle East trade flows are expected to support freight and charter markets during the remainder of the summer period. On the other side, China's official manufacturing PMI fell to 49.2 in July (from 50.3), returning to contraction after four months of expansion. The deterioration in both domestic and export demand points to softer demand for containerised imports of raw materials and intermediate goods, as well as slower growth in container exports in the coming months. If export demand continues to weaken, container shipping volumes on the major Asia–Europe and Transpacific trade lanes are likely to come under pressure.

While global container trade is still expected to continue growing during 2026 (+3.0% year-on-year in billion TEU-miles), fleet growth is forecast to exceed demand growth, supported by a historically large orderbook representing approximately 38% of the existing fleet. In addition, any eventual normalisation of Red Sea routing would reduce tonne-mile demand and increase effective vessel supply – meaning that for 2027, container demand is forecast to decrease by -5.8% in billion TEU-miles.

Delphis has 4 x 6,000 TEU (average age 1.8y) on the water and 1 NB 1,400 TEU container vessel. All vessels are employed under 10 to 15-year time charter contracts.

Bochem – Chemical Markets6

Chemical tanker markets remained relatively resilient during the second quarter of 2026 despite significant disruption to global trade flows following the closure of the Strait of Hormuz. While chemical trade volumes temporarily declined and tanker transits through the region fell sharply, freight markets benefited from vessel dislocations, supply chain reconfiguration and longer voyage distances on selected routes. Spot freight rates remained above pre-conflict levels, supported by strong export activity from both the United States and Asia. US producers continued to benefit from a feedstock cost advantage, increasing exports to Europe, Latin America and Asia, while Chinese exporters leveraged strong inventories and feedstock flexibility to maintain robust regional trade flows.

As the quarter progressed, market participants adapted to the new operating environment, with chemical cargoes increasingly rerouted between regions. Demand for aromatics and petrochemical feedstocks remained broadly healthy, supported by inventory replenishment and shifting sourcing patterns. These developments generated additional tonne-mile demand on several long-haul corridors, partly offsetting reduced activity in the Middle East. At the same time, firm conditions in adjacent product tanker markets helped support vessel utilisation across the chemical tanker sector.

Looking ahead, the market outlook for the second half of 2026 remains constructive but subject to elevated uncertainty. The gradual normalisation of Hormuz transits should support a recovery in trade activity, although chemical cargo flows may take longer than crude oil and refined products to return to historical patterns. Furthermore, the sector faces a sizeable orderbook, with a meaningful number of chemical and product tanker deliveries scheduled through 2026-2028. While expected growth in seaborne chemical trade should absorb part of this additional capacity, the pace of demand recovery and vessel deliveries will be key determinants of freight market performance.

Bochem’s chemical tanker fleet comprises out of 8 delivered vessels, and 8 NB vessels (average age <1y). They are employed under a 10-year time charter (8 vessels), under a 7-year time charter (6 vessels), and in a spot pool (2 vessels).

Bochem performance highlights:

 TCE Q2 2026QTD Q3 202625k DWT stainless Steel (Pool)22,021 USD/day22,350 Windcat – Offshore Energy Markets7

The offshore energy market remained robust during the second quarter of 2026 despite a challenging investment backdrop for the wider offshore wind industry. While project sanctioning activity remained subdued, with only limited new final investment decisions recorded during the period, offshore wind construction, commissioning and operations & maintenance activity continued at high levels across Europe and Asia. A near-record pipeline of projects under construction supported strong demand for both CSOVs and CTVs, resulting in high utilisation and healthy chartering activity.

The European CSOV market remained particularly strong throughout the quarter. High fleet utilisation, limited prompt vessel availability and continued demand from offshore wind installation and maintenance campaigns supported attractive charter rates. Premium CSOVs were largely committed through the summer season, with charter rates typically ranging between EUR 50,000 and EUR 75,000 per day. Demand broadened beyond offshore wind as oil and gas operators increasingly adopted walk-to-work solutions for offshore maintenance activities. This growing crossover demand helped absorb additional capacity entering the market and further strengthened utilisation levels. European Tier-1 CSOV utilisation remained close to full employment, while average charter rates increased year-on-year. Looking ahead to the second half of 2026, market fundamentals remain supportive. Offshore wind construction activity across Europe, particularly in the Baltic Sea and North Sea, is expected to sustain strong demand for offshore support vessels, while emerging opportunities in the oil and gas sector provide an additional source of employment for CSOVs. However, visibility beyond 2026 remains more balanced with the rapid CSOV fleet expansion.

The CTV market also delivered solid performance during the quarter. Vessel availability tightened significantly ahead of the summer maintenance season, with most vessels fixed on contracts and only limited spot capacity available. Strong utilisation across Northwest Europe supported stable charter rates at historically attractive levels. Continued growth in offshore wind operational capacity and increasing maintenance requirements provided a supportive backdrop for vessel demand, while newbuild ordering activity remained disciplined.

Windcat has 3 (+4NB) CSOVs (average age <1y), and 60 (+3NB) CTVs (average age 10.4y).

Windcat performance highlights:

 TCE Q2 2026QTD Q3 2026CSOV 64,45150,511 (65% fixed)CTV3,5653,765 (98% fixed) CONFERENCE CALL
The call will be a webcast with an accompanying slideshow. You can find the details of this conference call below and on the “Investor Relations” page of the website. The presentation, recording & transcript will also be available on this page.

Webcast Information Event Type: Video conference call with slide presentationEvent Date:27 August 2026Event Time:8 a.m. EST / 2 p.m. CETEvent Title: “Q2 2026 Earnings Conference Call”Event Site/URL:  https://events.teams.microsoft.com/event/9fcf4513-4ad3-44ec-8908-7058dfe26b88@d0b2b045-83aa-4027-8cf2-ea360b91d5e4 To attend this conference call, please register via the following link.

Telephone participants who are unable to pre-register may dial in to the respective number of their location (to be found here). The Phone conference ID is the following: 244 207 376#

Contact

CMB.TECH
Katrien Hennin
Head of Marketing and Communications
+32 499 39 34 70
[email protected]

Joris Daman
Head of Investor Relations
Tel: +32 498 61 71 11
[email protected]

Publication Q3 2026 results – 26 November 2026

About CMB.TECH

CMB.TECH (all capitals) is one of the largest listed, diversified and future-proof maritime groups in the world with a combined fleet of about 250 vessels: dry bulk vessels, crude oil tankers, chemical tankers, container vessels and offshore energy vessels. CMB.TECH also offers hydrogen and ammonia fuel to customers, through own production or third-party producers.

CMB.TECH is headquartered in Antwerp, Belgium, and has offices across Europe, Asia and Africa.

CMB.TECH is listed on Euronext Brussels and the NYSE under the ticker symbol “CMBT” and on Euronext Oslo Børs under the ticker symbol “CMBTO”.

More information can be found at https://cmb.tech

Forward-Looking Statements

Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbour protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The Company desires to take advantage of the safe harbour provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbour legislation. The words "believe", "anticipate", "intends", "estimate", "forecast", "project", "plan", "potential", "may", "should", "expect", "pending" and similar expressions identify forward-looking statements.

The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, our management's examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs or projections.

In addition to these important factors, other important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include the failure of counterparties to fully perform their contracts with us, the strength of world economies and currencies, general market conditions, including fluctuations in charter rates and vessel values, changes in demand for tanker vessel capacity, changes in our operating expenses, including bunker prices, dry-docking and insurance costs, the market for our vessels, availability of financing and refinancing, charter counterparty performance, ability to obtain financing and comply with covenants in such financing arrangements, changes in governmental rules and regulations or actions taken by regulatory authorities, potential liability from pending or future litigation, general domestic and international political conditions, potential disruption of shipping routes due to accidents or political events, vessels breakdowns and instances of off-hires and other factors. Please see our filings with the United States Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties.

This information is published in accordance with the requirements of the Continuing Obligations on Euronext Oslo Børs.

Condensed consolidated interim statement of financial position (unaudited)

(in thousands of USD)

          June 30, 2026  December 31, 2025ASSETS             Non-current assets      Vessels          6,875,419  6,323,773Assets under construction          532,660  739,373Right-of-use assets          4,935  4,847Other tangible assets          48,002  23,981Intangible assets          16,055  12,710Goodwill          177,022  177,022Receivables          98,018  97,116Investments          154,217  111,346Deferred tax assets          2,541  2,850       Total non-current assets  7,908,869  7,493,018       Current assets      Inventory          120,674  77,175Trade and other receivables          415,688  320,843Current tax assets          2,828  4,912Short-term investments          8,271  —Cash and cash equivalents          151,574  146,529   699,035  549,459       Non-current assets held for sale          219,985  363,097       Total current assets  919,020  912,556       TOTAL ASSETS  8,827,889  8,405,574              EQUITY and LIABILITIES             Equity      Share capital          343,440  343,440Share premium          1,689,882  1,817,557Translation reserve          5,146  9,502Hedging reserve          1,044  90Treasury shares          (284,508)  (284,508)Retained earnings          1,365,990  737,239       Equity attributable to owners of the Company  3,120,994  2,623,320       Non-current liabilities      Bank loans          2,869,323  2,839,590Other borrowings          1,998,055  1,876,795Lease liabilities          4,014  3,368Other payables          15,072  20Employee benefits          1,176  1,180Deferred tax liabilities          26  485       Total non-current liabilities  4,887,666  4,721,438       Current liabilities      Trade and other payables          235,139  222,492Current tax liabilities          2,807  8,288Bank loans          195,082  351,170Other notes          203,619  203,287Other borrowings          180,981  273,898Lease liabilities          1,587  1,681Provisions          14  —       Total current liabilities  819,229  1,060,816       TOTAL EQUITY and LIABILITIES  8,827,889  8,405,574               Condensed consolidated interim statement of profit or loss (unaudited)

(in thousands of USD except per share amounts)

          2026  2025   Jan. 1 - June 30, 2026  Jan. 1 - June 30, 2025Shipping income      Revenue  1,223,573  622,852Gains on disposal of vessels/other tangible assets  394,871  103,791Other operating income  37,055  20,155Total shipping income  1,655,499  746,798       Operating expenses      Raw materials and consumables          (2,003)          (5,128)Voyage expenses and commissions          (249,168)  (123,742)Vessel operating expenses          (252,956)  (175,473)Charter hire expenses          (3,974)  (1,620)Depreciation tangible assets          (216,568)  (162,767)Amortisation intangible assets          (1,428)  (1,602)Impairment reversals          729          (3,573)General and administrative expenses  (58,558)  (56,395)Total operating expenses  (783,926)  (530,300)       RESULT FROM OPERATING ACTIVITIES  871,573  216,498       Finance income  21,112  25,707Finance expenses  (178,981)  (208,147)Net finance expenses  (157,869)  (182,440)       Share of profit (loss) of equity accounted investees (net of income tax)          21,495  1,571       PROFIT (LOSS) BEFORE INCOME TAX  735,199  35,629       Income tax benefit (expense)  (1,985)  (2,840)       PROFIT (LOSS) FOR THE PERIOD  733,214  32,789       Attributable to:      Owners of the company  733,214  51,766Non-controlling interest  —          (18,977)       Basic earnings per share  2.53  0.27Diluted earnings per share  2.53  0.27       Weighted average number of shares (basic)  290,169,769  194,216,835Weighted average number of shares (diluted)  290,169,769  194,216,835                      Condensed consolidated interim statement of comprehensive income (unaudited)

(in thousands of USD)

          2026  2025   Jan. 1 - June 30, 2026  Jan. 1 - June 30, 2025       Profit/(loss) for the period  733,214  32,789       Other comprehensive income (expense), net of tax      Items that will never be reclassified to profit or loss:      Remeasurements of the defined benefit liability (asset)          —          —       Items that are or may be reclassified to profit or loss:      Foreign currency translation differences  (4,356)  11,330Cash flow hedges - effective portion of changes in fair value  954  (1,794)       Other comprehensive income (expense), net of tax  (3,402)  9,536       Total comprehensive income (expense) for the period  729,812  42,325       Attributable to:      Owners of the company  729,812  61,302Non-controlling interest  —  (18,977)               Condensed consolidated interim statement of changes in equity (unaudited)

(In thousands of USD)

 Share capitalShare premiumTranslation reserveHedging reserveTreasury sharesRetained earningsEquity attributable to owners of the CompanyNon-controlling interestTotal equity          Balance at January 1, 2025239,148460,486(2,045)2,145(284,508)777,0981,192,324—1,192,324          Profit (loss) for the period        —        —        —        —        —51,76651,766(18,977)32,789Total other comprehensive income (expense)        —        —11,330(1,794)        —        —9,536—9,536Total comprehensive income (expense)        —        —11,330(1,794)        —51,76661,302(18,977)42,325          Transactions with owners of the company         Business Combination - Initial purchase        —        —        —        —        —        ——1,460,354        1,460,354Business Combination - Subsequent purchases        —        —        —        —        —        73,70573,705(210,771)(137,066)Dividends to Non-controlling interest        —        —        —        —        —        ——(5,095)(5,095)Total transactions with owners        —        —        —        —        —        73,70573,7051,244,4881,318,193          Balance at June 30, 2025239,148460,4869,285351(284,508)902,5691,327,3311,225,5112,552,842                               Share capitalShare premiumTranslation reserveHedging reserveTreasury sharesRetained earningsEquity attributable to owners of the CompanyNon-controlling interestTotal equity          Balance at January 1, 2026343,4401,817,5579,50290(284,508)737,2392,623,320—2,623,320          Profit (loss) for the period        —        —        —        —        —733,214733,214—733,214Total other comprehensive income (expense)        —        —(4,356)954        ——(3,402)—(3,402)Total comprehensive income (expense)        —        —(4,356)954        —733,214729,812—729,812          Transactions with owners of the company         Dividends to equity holders        —(127,675)        —        —        —(104,462)(232,137)—(232,137)Total transactions with owners—(127,675)———(104,462)(232,137)—(232,137)          Balance at June 30, 2026343,4401,689,8825,1461,044(284,508)1,365,9903,120,994—3,120,994                      Condensed consolidated interim statement of cash flows (unaudited)

(in thousands of USD)

          2026  2025   Jan. 1 - June 30, 2026  Jan. 1 - June 30, 2025       Net cash from (used in) operating activities  417,287  73,098              Net cash from (used in) investing activities  (83,108)  (1,381,329)              Net cash from (used in) financing activities  (328,475)  1,424,516              Net increase (decrease) in cash and cash equivalents  5,704  116,285       Net cash and cash equivalents at the beginning of the period  146,529          38,869Effect of changes in exchange rates  (659)          (106)       Net cash and cash equivalents at the end of the period  151,574  155,048               1 Source: Clarksons SIN, NOAA, Citi, Ocean Analytics, Doric, Commodore Research
2 On 1 January 2026, the Baltic Exchange recalibrated its Capesize index by changing the standard reference vessel from a 180,000 DWT ship to a 182,000 DWT “eco” design. This update increased the baseline Baltic Capesize Index (BCI) time charter average by roughly USD 3,500 per day
3 Source: Clarksons SIN, IEA, Goldman Sachs, Bloomberg, CNBC, Citi, Vortexa
4 Announced vessels sales that have not yet been delivered to new owners are already excluded
5 Source: Clarksons
6 Source: Stolt Nielsen, Clarksons, S&P Global, SSY
7 Source: Clarksons

CMBT_Q2_2026_Earnings_release_ENG

CMB.TECH NV (CMBT) Q2 2026 Earnings Call Transcript

BlackRock Inc. purchased a new position in shares of Bio-Techne Corp (NASDAQ:TECH – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 14,025,816 shares of the biotechnology company’s stock, valued at approximately $990,924,000. BlackRock Inc. owned about 8.96% of Bio-Techne at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of TECH. Danske Bank A S purchased a new position in shares of Bio-Techne in the fourth quarter valued at about $29,000. Measured Wealth Private Client Group LLC bought a new stake in Bio-Techne in the third quarter worth $32,000. iSAM Funds UK Ltd purchased a new position in shares of Bio-Techne during the 3rd quarter worth about $33,000. Avalon Trust Co purchased a new stake in shares of Bio-Techne in the second quarter worth approximately $42,000. Finally, Los Angeles Capital Management LLC purchased a new position in Bio-Techne during the 4th quarter valued at $39,000. 98.95% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades Several research firms recently commented on TECH. William Blair downgraded shares of Bio-Techne from an “outperform” rating to a “market perform” rating in a research note on Thursday, June 25th. Deutsche Bank Aktiengesellschaft downgraded shares of Bio-Techne from a “buy” rating to a “hold” rating and set a $73.00 target price on the stock. in a research note on Friday, June 26th. Piper Sandler started coverage on shares of Bio-Techne in a research note on Thursday, June 11th. They set a “neutral” rating and a $65.00 price target for the company. Benchmark reiterated a “hold” rating on shares of Bio-Techne in a report on Wednesday. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Bio-Techne in a research note on Tuesday, August 4th. Two equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Bio-Techne presently has an average rating of “Hold” and a consensus price target of $68.92.

View Our Latest Analysis on Bio-Techne Bio-Techne Price Performance Shares of NASDAQ TECH opened at $72.32 on Friday. Bio-Techne Corp has a 52 week low of $43.19 and a 52 week high of $72.62. The business’s 50 day moving average price is $69.28 and its 200 day moving average price is $59.54. The company has a quick ratio of 3.35, a current ratio of 4.55 and a debt-to-equity ratio of 0.09. The firm has a market cap of $11.32 billion, a P/E ratio of 62.89, a P/E/G ratio of 8.61 and a beta of 1.28.

Bio-Techne (NASDAQ:TECH – Get Free Report) last posted its earnings results on Wednesday, August 12th. The biotechnology company reported $0.52 EPS for the quarter, meeting analysts’ consensus estimates of $0.52. The firm had revenue of $321.19 million for the quarter, compared to analysts’ expectations of $314.63 million. Bio-Techne had a return on equity of 13.23% and a net margin of 14.97%.The company’s quarterly revenue was up 1.3% on a year-over-year basis. During the same period last year, the firm earned $0.53 EPS. On average, sell-side analysts expect that Bio-Techne Corp will post 1.76 earnings per share for the current year.

Bio-Techne Increases Dividend The company also recently announced a quarterly dividend, which will be paid on Friday, September 4th. Shareholders of record on Monday, August 24th will be issued a $0.65 dividend. This represents a $2.60 annualized dividend and a yield of 3.6%. The ex-dividend date is Monday, August 24th. This is a positive change from Bio-Techne’s previous quarterly dividend of $0.08. Bio-Techne’s dividend payout ratio (DPR) is presently 27.83%.

About Bio-Techne (Free Report)

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.

Recommended Stories Five stocks we like better than Bio-Techne Blueprint for a Boom: SEC Clears the Crypto Runway Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss Advance Auto Parts Plunged, But Its Turnaround Is Still Working Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?

Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Bio-Techne Corporation (NASDAQ: TECH) to Merck KGaA for $73.00 per share in cash. Halper Sadeh encourages Bio-Techne shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Bio-Techne and its board of directors violat.

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

The proposed transactions may contain terms that could limit superior competing offers.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Payoneer Global Inc. (NASDAQ: PAYO)'s sale to Nuvei for $7.40 per share in cash. If you are a Payoneer shareholder, click here to learn more about your rights and options.

Bio-Techne Corporation (NASDAQ: TECH)'s sale to Merck KGaA for $73.00 per share in cash. If you are a Bio-Techne shareholder, click here to learn more about your rights and options.

Colony Bankcorp, Inc. (NYSE: CBAN)'s merger with First Reliance Bancshares, Inc. If you are a Colony shareholder, click here to learn more about your rights and options.

On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

, /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) is issuing a correction to its dividend announcement released yesterday. The initial version incorrectly stated the shareholder of record date as August 17, 2026. The correct shareholder of record date is August 24, 2026. All other information contained in the dividend announcement remains unchanged.

Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2026. The quarterly dividend will be payable August 28, 2026, to all common shareholders of record on August 24, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis.

Bio‑Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high‑quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer‑focused brands: R&D Systems™, Bio‑Techne Spatial™, and Bio‑Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision‑making. Bio‑Techne operates in 34 locations worldwide and employs approximately 3,000 people. In fiscal year 2026, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories. For more information on Bio-Techne and its brands, please visit www.bio-techne.com or follow the company on social media at LinkedIn, X, or YouTube. 

Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding potential future repurchase of Bio-Techne common stock. The following important factors, among others, have affected and, in the future, could affect the Company's actual results and future share price: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

Contact:

David Clair, Vice President, Investor Relations

[email protected]

612-656-4416

SOURCE Bio-Techne Corporation

Techne (TECH - Free Report) came out with quarterly earnings of $0.52 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.53 per share a year ago. These figures are adjusted for non-recurring items.

A quarter ago, it was expected that this maker of medical testing and diagnostic products would post earnings of $0.55 per share when it actually produced earnings of $0.53, delivering a surprise of -3.64%.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

Techne, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $321.19 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.26%. This compares to year-ago revenues of $316.96 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Techne shares have added about 22.7% since the beginning of the year versus the S&P 500's gain of 12.9%.

What's Next for Techne?While Techne has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Techne was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #5 (Strong Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.46 on $293.41 million in revenues for the coming quarter and $2.04 on $1.26 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Zealand Pharma A/S (ZLDPF - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on August 13.

This company is expected to post quarterly loss of $0.42 per share in its upcoming report, which represents a year-over-year change of -102.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Zealand Pharma A/S's revenues are expected to be $81.55 million, down 94.1% from the year-ago quarter.

, /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2026.

Fourth Quarter FY2026 Highlights

Fourth quarter organic revenue increased by 3% (1% reported) to $321.2 million. Full year organic and reported revenue remained flat at $1.2 billion. GAAP EPS increased to $0.35 from $(0.11) one year ago. Delivered adjusted EPS was $0.52, down from $0.53 one year ago. Full year GAAP EPS increased to $1.16 versus $0.46 one year ago. Full year adjusted EPS was $1.93, up from $1.92 one year ago. As previously announced on June 25, 2026, Bio-Techne entered into an agreement to be acquired by Merck KGaA, Darmstadt, Germany for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion. "Bio-Techne ended fiscal 2026 with improved performance and solid execution across the business, reflecting the value our differentiated solutions bring across biopharma, research and diagnostic workflows," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "We continue to make progress toward completing Bio-Techne's acquisition by Merck KGaA, Darmstadt, Germany, and look forward to the opportunities this transaction is expected to create for our customers and employees."

Conference Call

In light of the announced transaction with Merck KGaA, Darmstadt, Germany, Bio-Techne is no longer holding investor conference calls for quarterly results.

Fourth Quarter Fiscal 2026

Revenue

Net sales for the fourth quarter increased 1% to $321.2 million. Organic growth increased 3% compared to the prior year. Non-recurring prior year revenue from a business held-for-sale had an unfavorable impact of 2% and foreign currency exchange did not have a material impact.

GAAP Earnings Results

GAAP EPS was $0.35 per diluted share versus $(0.11) in the same quarter last year. GAAP operating income for the fourth quarter of fiscal 2026 was $74.3 million compared to an operating loss of $23.9 million in the fourth quarter of fiscal 2025. GAAP operating margin was 23.1% compared to (7.5)% in the fourth quarter of fiscal 2025. Current quarter GAAP operating margin was favorably impacted by a non-recurring impairment charge in the prior year.

Non-GAAP Earnings Results

Adjusted EPS decreased to $0.52 per diluted share compared to $0.53 in the same quarter last year. Adjusted operating income increased to $103.4 million in the fourth quarter of fiscal 2026 compared to $101.3 million in the fourth quarter of fiscal 2025. Adjusted operating margin was 32.2% for the fourth quarter of fiscal 2026 compared to 32.0% in the fourth quarter of fiscal 2025. Adjusted operating margin was favorably impacted by profitability initiatives and the Exosome Diagnostics divestiture, partially offset by unfavorable product mix.

Full Year Fiscal 2026

Revenue

Net sales for the full year fiscal 2026 remained flat from the prior year at $1.2 billion. Organic revenue remained flat from the prior year. Foreign currency exchange had a favorable impact of 2% and a business held-for-sale had an unfavorable impact of 2%.

GAAP Earnings Results

GAAP EPS was $1.16 per diluted share, compared to $0.46 last fiscal year. GAAP operating income for full year fiscal 2026 increased 146% to $251.9 million, compared to $102.3 million in the full year fiscal 2025. GAAP operating margin was 20.7% compared to 8.4% in the full year fiscal 2025. GAAP operating margin was favorably impacted by a non-recurring impairment charge in the prior year, a non-recurring arbitration award in the prior year, and a recovery of assets held-for-sale.

Non-GAAP Earnings Results

Adjusted EPS increased to $1.93 per diluted share, compared to $1.92 last fiscal year. Adjusted operating income for fiscal 2026 increased 1% to $386.1 million, compared to $383.6 million for fiscal 2025. Adjusted operating margin was favorably impacted by profitability initiatives and the Exosome Diagnostics divestiture.

Segment Results

Management uses adjusted operating results to monitor and evaluate performance of the Company's business segments, as highlighted below.

Protein Sciences Segment

The Company's Protein Sciences segment is one of the world's leading suppliers of specialized proteins such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biopharma and academic research communities. Additionally, the segment provides an array of platforms essential in various areas of protein analysis. The Protein Sciences segment's fourth quarter fiscal 2026 net sales were $231.2 million, an increase of 2% from $226.5 million in the fourth quarter of fiscal 2025. As of December 31, 2023, a business within the Protein Sciences segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment's operating results for both periods presented. Organic revenue increased 1% for the fourth quarter of fiscal 2026, with foreign currency exchange having a favorable impact of 1%. The Protein Sciences segment's operating margin decreased to 42.0% in the fourth quarter of fiscal 2026 compared to 43.6% in the fourth quarter of fiscal 2025. The segment's operating margin decreased primarily due to unfavorable volume and product mix.

Protein Sciences segment's full year fiscal 2026 net sales were $874.6 million, an increase of 1% from $870.2 million for full year fiscal 2025. Organic revenue for the segment decreased 1% for the fiscal year, with foreign currency exchange having a favorable impact of 2%. Protein Sciences segment's operating margin was 41.1% in fiscal 2026 compared to 42.6% in fiscal 2025. The segment's operating margin was impacted by unfavorable volume and product mix.

Diagnostics and Spatial Biology Segment

The Company's Diagnostics and Spatial Biology segment develops and provides spatial biology products, carrier screening and oncology kits. The Diagnostics and Spatial Biology segment also provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays and other bulk and custom reagents for the in vitro diagnostic market. The Diagnostics and Spatial Biology segment's fourth quarter fiscal 2026 net sales remained flat at $90.1 million, as compared to $89.7 million in the fourth quarter of fiscal 2025. As of June 30, 2025, a business within the Diagnostics and Spatial Biology segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment's fiscal 2026 operating results. Organic revenue increased 8% for the fourth quarter of fiscal 2026, with foreign exchange not having a material impact. The held-for-sale business had an unfavorable impact of 8%. The Diagnostics and Spatial Biology segment's operating margin increased to 11.2% in the fourth quarter of fiscal 2026 compared to 6.0% in the fourth quarter of fiscal 2025. The segment's operating margin was favorably impacted by the Exosome Diagnostics divestiture, favorable volume growth, and ongoing profitability initiatives.

The Diagnostics and Spatial Biology segment's full year fiscal 2026 net sales were $336.4 million, a decrease of 3% from $346.3 million for the full year fiscal 2025. Organic growth for the segment was 4%, with foreign currency exchange having a favorable impact of 1%. A business held-for-sale had an unfavorable impact of 8%. The Diagnostics and Spatial Biology segment's operating margin was 11.2% in fiscal 2026 compared to 6.2% in fiscal 2025. The segment's operating margin was impacted by the divestiture of Exosome Diagnostics, favorable volume growth, and ongoing profitability initiatives.

About Bio-Techne

Bio‑Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high‑quality reagents, analytical instruments, and precision diagnostics.  Its portfolio is organized into three customer‑focused brands: R&D Systems™, Bio‑Techne Spatial™, and Bio‑Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision‑making. Bio‑Techne operates in 34 locations worldwide and employs approximately 3,000 people. In fiscal year 2026, the company generated over $1.2 billion in net sales.  Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories. For more information on Bio-Techne and its brands, please visit www.bio-techne.com or follow the company on social media at LinkedIn, X, or YouTube. 

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements use words and variations of words, such as "will," "plan," "continue," "believe," "outlook," "expect," and "predict." These statements are made as of the date of this press release, are based on current expectations of future events, and thus are inherently subject to a number of risks and uncertainties, many of which involve factors or circumstances beyond the Company's control. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. These risks, uncertainties, and other factors include, without limitation: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

For additional information concerning these risks, uncertainties, and other factors, see the section titled "Risk Factors" in the Company's most recent annual report on Form 10-K as filed with the Securities and Exchange Commission. We undertake and we expressly disclaim any obligation to update or revise any forward-looking statements due to new information, changed assumptions, or future events, except as required by law. Investors are cautioned not to place undue reliance on forward-looking statements.

Non-GAAP Financial Measures:

The Company's financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (GAAP). This press release contains financial measures that have not been calculated in accordance with GAAP. These non-GAAP measures include:

Organic revenue and organic revenue growth Adjusted gross margin Earnings before interest, taxes, depreciation, and amortization (EBITDA) Adjusted EBITDA Adjusted operating income Adjusted operating margin Adjusted tax rate Adjusted net earnings Adjusted diluted earnings per share These non-GAAP measures should not be considered in isolation or as a substitute for any measure derived in accordance with GAAP and may also be inconsistent with similar measures presented by other companies. Reconciliations of these measures to the applicable most closely comparable GAAP measures, and reasons for the Company's use of these measures, are presented in the attached pages.

Contact:

David Clair, Vice President, Investor Relations

[email protected]

612-656-4416

BIO-TECHNE CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS

(In thousands, except per share data)

(Unaudited)

Quarter Ended

Year Ended

June 30, 

June 30, 

2026

2025

2026

2025

Net sales

$

321,191

$

316,964

$

1,215,039

$

1,219,635

Cost of sales

109,797

118,152

415,968

429,363

Gross margin

211,394

198,812

799,071

790,272

Operating expenses:

Selling, general and administrative

113,172

196,640

452,415

588,521

Research and development

23,945

26,032

94,766

99,496

Total operating expenses

137,117

222,672

547,181

688,017

Operating income

74,277

(23,860)

251,890

102,255

Other income (expense)

(3,596)

1,001

(11,210)

(3,792)

Earnings before income taxes

70,681

(22,859)

240,680

98,463

Income taxes

16,059

(5,182)

58,818

25,063

Net earnings

$

54,622

$

(17,677)

$

181,862

$

73,400

Earnings per share:

Basic

$

0.35

$

(0.11)

$

1.17

$

0.47

Diluted

$

0.35

$

(0.11)

$

1.16

$

0.46

Weighted average common shares outstanding:

Basic

156,090

154,913

155,963

157,521

Diluted

157,025

155,757

157,009

159,717

BIO-TECHNE CORPORATION

RECONCILIATION OF ADJUSTED GROSS MARGIN AND ADJUSTED GROSS MARGIN PERCENTAGE

(In thousands)

(Unaudited)

Quarter Ended

Year Ended

June 30, 

June 30, 

2026

2025

2026

2025

Total consolidated net sales

$

321,191

$

316,964

$

1,215,039

$

1,219,635

Business held-for-sale(1)

—

—

5,439

4,152

Revenue from recurring operations

$

321,191

$

316,964

$

1,209,600

$

1,215,483

Gross margin - GAAP

$

211,394

$

198,812

$

799,071

$

790,272

Gross margin percentage - GAAP

65.8

%

62.7

%

65.8

%

64.8

%

Identified adjustments:

Costs recognized upon sale of acquired inventory

$

—

$

197

$

—

$

751

Amortization of intangibles

9,422

10,569

37,799

44,035

Stock-based compensation, inclusive of employer taxes

282

288

1,534

1,298

Restructuring and restructuring-related costs

1,049

12,141

5,805

20,094

Impact of business held-for-sale(1)

—

—

(2,581)

(147)

Adjusted gross margin

$

222,147

$

222,007

$

841,628

$

856,303

Adjusted gross margin percentage(2)

69.2

%

70.0

%

69.6

%

70.4

%

(1)

June 30, 2025 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023.
June 30, 2026 amounts relate to the Diagnostics and Spatial Biology segment business that met the held-for-sale criteria on June
30, 2025.

(2)

Adjusted gross margin percentage excludes both revenue and gross margin of the businesses that met the held-for-sale criteria
during the respective periods.

BIO-TECHNE CORPORATION

RECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA

(In thousands)

(Unaudited)

Quarter Ended

Year Ended

June 30, 

June 30, 

2026

2025

2026

2025

Net earnings

$

54,622

$

(17,677)

$

181,862

$

73,400

Net interest expense (income)

750

1,593

5,405

4,623

Depreciation and amortization

24,169

27,111

97,359

109,903

Income taxes

16,059

(5,182)

58,818

25,063

EBITDA

95,600

5,845

343,444

212,989

Amortization of Wilson Wolf intangible assets

2,490

2,490

9,959

9,959

Acquisition related expenses and other

1,782

4,010

8,570

13,489

Certain litigation charges

143

1,220

5,513

41,827

Stock-based compensation, inclusive of employer taxes

5,375

4,653

42,637

42,158

Restructuring and restructuring-related costs

6,858

13,205

21,059

28,231

Investment loss and other non-operating loss

3,695

—

5,009

—

Impairment (Recovery) of assets held-for-sale

—

84,157

(6,789)

80,503

Impact of business held-for-sale(1)

—

—

2,573

479

Adjusted EBITDA

$

115,943

$

115,580

$

431,975

$

429,635

(1)

June 30, 2025 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023.
June 30, 2026 amounts relate to the Diagnostics and Spatial Biology segment business that met the held-for-sale criteria on June
30, 2025.

BIO-TECHNE CORPORATION

RECONCILIATION OF ADJUSTED OPERATING INCOME AND ADJUSTED OPERATING MARGIN PERCENTAGE

(In thousands)

(Unaudited)

Quarter Ended

Year Ended

June 30, 

June 30, 

2026

2025

2026

2025

Total consolidated net sales

$

321,191

$

316,964

$

1,215,039

$

1,219,635

Business held-for-sale(1)

—

—

5,439

4,152

Revenue from recurring operations

$

321,191

$

316,964

$

1,209,600

$

1,215,483

Operating income - GAAP

$

74,277

$

(23,860)

$

251,890

$

102,255

Operating income percentage - GAAP

23.1

%

(7.5)

%

20.7

%

8.4

%

Identified adjustments:

Amortization of intangibles

15,070

18,185

61,181

75,321

Acquisition related expenses and other

1,636

3,767

7,986

12,815

Certain litigation charges

143

1,220

5,513

41,827

Stock-based compensation, inclusive of employer taxes

5,375

4,653

42,637

42,158

Restructuring and restructuring-related costs

6,858

13,205

21,059

28,231

Impairment (Recovery) of assets held-for-sale

—

84,157

(6,789)

80,503

Impact of business held-for-sale(1)

—

—

2,573

479

Adjusted operating income

$

103,359

$

101,327

$

386,050

$

383,589

Adjusted operating margin percentage(2)

32.2

%

32.0

%

31.9

%

31.6

%

(1)

June 30, 2025 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023.
June 30, 2026 amounts relate to the Diagnostics and Spatial Biology segment business that met the held-for-sale criteria on June
30, 2025.

(2)

Adjusted operating margin percentage excludes both revenue and operating margin for the businesses that met the held-for-sale
criteria during the respective periods.

BIO-TECHNE CORPORATION

RECONCILIATION OF NON-GAAP ADJUSTED TAX RATE

(In percentages)

(Unaudited)

Quarter Ended

Year Ended

June 30, 

June 30, 

2026

2025

2026

2025

GAAP effective tax rate

22.7

%

22.7

%

24.4

%

25.5

%

Discrete items

(0.7)

13.9

1.3

0.8

Annual forecast update

3.7

(10.3)

—

—

Long-term GAAP tax rate

25.7

%

26.3

%

25.7

%

26.3

%

Rate impact items

Stock based compensation

(1.1)

%

(0.9)

%

(2.0)

%

(3.1)

%

Other

(2.3)

(3.9)

(1.4)

(1.7)

Total rate impact items

(3.4)

%

(4.8)

%

(3.4)

%

(4.8)

%

Non-GAAP adjusted tax rate

22.3

%

21.5

%

22.3

%

21.5

%

BIO-TECHNE CORPORATION

RECONCILIATION OF ADJUSTED NET EARNINGS AND ADJUSTED EARNINGS PER SHARE

(In thousands, except per share data)

(Unaudited)

Quarter Ended

Year Ended

June 30, 

June 30, 

2026

2025

2026

2025

Net earnings before taxes - GAAP

$

70,681

$

(22,859)

$

240,680

$

98,463

Identified adjustments:

Amortization of intangibles

15,070

18,185

61,181

75,321

Amortization of Wilson Wolf intangible assets

2,490

2,490

9,959

9,959

Acquisition related expenses and other

1,782

4,010

8,570

13,489

Certain litigation charges

143

1,220

5,513

41,827

Stock-based compensation, inclusive of employer taxes

5,375

4,653

42,637

42,158

Restructuring and restructuring-related costs

6,858

13,205

21,059

28,231

Investment loss and other non-operating loss

3,695

—

5,009

—

Impairment (Recovery) of assets held-for-sale

—

84,157

(6,789)

80,503

Impact of business held-for-sale(1)

—

—

2,573

479

Net earnings before taxes - Adjusted

$

106,094

$

105,061

$

390,392

$

390,430

Non-GAAP tax rate

22.3

%

21.5

%

22.3

%

21.5

%

Non-GAAP tax expense

$

23,658

$

22,589

$

87,057

$

83,973

Non-GAAP adjusted net earnings

$

82,436

$

82,472

$

303,335

$

306,457

Earnings per share - diluted - Adjusted

$

0.52

$

0.53

$

1.93

$

1.92

(1)

June 30, 2025 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023.
June 30, 2026 amounts relate to the Diagnostics and Spatial Biology segment business that met the held-for-sale criteria on June
30, 2025.

BIO-TECHNE CORPORATION

SEGMENT REVENUE

(In thousands)

(Unaudited)

Quarter Ended

Year Ended

June 30, 

June 30, 

2026

2025

2026

2025

Protein Sciences segment revenue

$

231,194

$

226,472

$

874,620

$

870,245

Diagnostics and Spatial Biology segment revenue

90,141

89,705

336,365

346,263

Other revenue(1)

—

—

5,439

4,152

lntersegment revenue

(144)

787

(1,385)

(1,025)

Consolidated revenue

$

321,191

$

316,964

$

1,215,039

$

1,219,635

(1)

June 30, 2025 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023.
June 30, 2026 amounts relate to the Diagnostics and Spatial Biology segment business that met the held-for-sale criteria on June
30, 2025.

BIO-TECHNE CORPORATION

SEGMENT OPERATING INCOME

(In thousands)

(Unaudited)

Quarter Ended

Year Ended

June 30, 

June 30, 

2026

2025

2026

2025

Protein Sciences segment operating income

$

97,073

$

98,790

$

359,401

$

370,353

Diagnostics and Spatial Biology segment operating income

10,069

5,384

37,698

21,324

Segment operating income

107,142

104,174

397,099

391,677

Corporate general, selling, and administrative

(3,783)

(2,847)

(11,049)

(8,088)

Adjusted operating income

103,359

101,327

386,050

383,589

Amortization of intangibles

(15,070)

(18,185)

(61,181)

(75,321)

Acquisition related expenses and other

(1,636)

(3,767)

(7,986)

(12,815)

Certain litigation charges

(143)

(1,220)

(5,513)

(41,827)

Stock-based compensation, inclusive of employer taxes

(5,375)

(4,653)

(42,637)

(42,158)

Restructuring and restructuring-related costs

(6,858)

(13,205)

(21,059)

(28,231)

(Impairment) Recovery of assets held-for-sale

—

(84,157)

6,789

(80,503)

Impact of business held-for-sale(1)

—

—

(2,573)

(479)

Operating income

$

74,277

$

(23,860)

$

251,890

$

102,255

(1)

June 30, 2025 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023.
June 30, 2026 amounts relate to the Diagnostics and Spatial Biology segment business that met the held-for-sale criteria on June
30, 2025.

BIO-TECHNE CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

June 30,

June 30,

2026

2025

ASSETS

Cash and equivalents

$

264,712

$

162,186

Accounts receivable, net

216,585

206,876

Inventories

195,744

189,446

Current assets held-for-sale

—

12,332

Other current assets

67,360

37,460

Total current assets

744,401

608,300

Property and equipment, net

231,836

245,719

Right of use assets

67,333

73,399

Goodwill and intangible assets, net

1,278,820

1,346,534

Other assets

264,336

283,916

Total assets

$

2,586,726

$

2,557,868

LIABILITIES AND STOCKHOLDERS' EQUITY

Accounts payable and accrued expenses

$

105,075

$

116,765

Contract liabilities

36,072

32,571

Income taxes payable

3,593

10,770

Operating lease liabilities - current

14,935

14,098

Other current liabilities

4,025

1,645

Total current liabilities

163,700

175,849

Deferred income taxes

19,308

6,169

Long-term debt obligations

200,000

346,000

Operating lease liabilities

74,152

83,960

Other long-term liabilities

21,345

27,082

Stockholders' equity

2,108,221

1,918,808

Total liabilities and stockholders' equity

$

2,586,726

$

2,557,868

BIO-TECHNE CORPORATION

CONDENSED CONSOLIDATED CASH FLOWS

(In thousands)

(Unaudited)

Year Ended

June 30, 

2026

2025

CASH FLOWS FROM OPERATING ACTIVITIES

Net earnings

$

181,862

$

73,400

Adjustments to reconcile net earnings to net cash provided by operating activities

Depreciation and amortization

97,359

109,903

Costs recognized on sale of acquired inventory

—

751

Deferred income taxes

13,196

(51,107)

Stock-based compensation expense

41,365

40,833

(Gain) Loss on equity method investment

(887)

(938)

Asset impairment restructuring

3,914

21,312

Recovery of assets held-for-sale

(6,789)

80,503

Other operating activities

(37,947)

12,899

Net cash provided by (used in) operating activities

292,073

287,556

CASH FLOWS FROM INVESTING ACTIVITIES

Proceeds from sale of available-for-sale investments

—

1,085

Additions to property and equipment

(28,850)

(31,006)

Distributions from Wilson Wolf

6,043

7,291

Investment in Spear Bio

—

(15,000)

Proceeds from sale of assets held-for-sale

4,617

2,447

Net cash provided by (used in) investing activities

(18,190)

(35,183)

CASH FLOWS FROM FINANCING ACTIVITIES

Cash dividends

(49,916)

(50,391)

Proceeds from stock option exercises

80,618

51,739

Long-term debt activity, net

(146,000)

27,000

Repurchases of common stock

(41,675)

(275,731)

Taxes paid on RSUs and net share settlements

(12,141)

(6,522)

Net cash provided by (used in) financing activities

(169,114)

(253,905)

Effect of exchange rate changes on cash and cash equivalents

(2,243)

11,927

Net increase (decrease) in cash and cash equivalents

102,526

10,395

Cash and cash equivalents at beginning of period

162,186

151,791

Cash and cash equivalents at end of period

$

264,712

$

162,186

Use of Non-GAAP Financial Measures:

This press release contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results. Investors are encouraged to review the reconciliations of non-GAAP financial measures used in this press release to their most directly comparable GAAP financial measures as provided with the financial statements attached to this press release.

Our non-GAAP financial measure of organic revenue and organic revenue growth represent revenue growth excluding revenue from acquisitions within the preceding 12 months, the impact of foreign currency, as well as the impact of businesses held-for-sale. Excluding these measures provides more useful period-to-period comparison of revenue results as it excludes the impact of foreign currency exchange rates, which can vary significantly from period to period, and revenue from acquisitions that would not be included in the comparable prior period. Revenues from businesses held-for-sale are excluded from our organic revenue calculation starting on the date they become held-for-sale as those revenues will not be comparative in future periods.

Our non-GAAP financial measures for adjusted gross margin, adjusted operating margin, adjusted EBITDA, and adjusted net earnings, in total and on a per share basis, exclude stock-based compensation, which is inclusive of the employer portion of payroll taxes on those stock awards, the costs recognized upon the sale of acquired inventory, amortization of acquisition intangibles, and restructuring and restructuring-related costs. Stock-based compensation is excluded from non-GAAP adjusted net earnings because of the nature of this charge, specifically the varying available valuation methodologies, subjective assumptions, variety of award types, and unpredictability of amount and timing of employer related tax obligations. The Company excludes amortization of purchased intangible assets, purchase accounting adjustments, including costs recognized upon the sale of acquired inventory, and other non-recurring items including gains or losses on goodwill and long-lived asset impairment charges, and one-time assessments from this measure because they occur as a result of specific events, and are not reflective of our internal investments, the costs of developing, producing, supporting and selling our products, and the other ongoing costs to support our operating structure. Costs related to restructuring and restructuring-related activities, including reducing overhead and consolidating facilities, are excluded because we believe they are not indicative of our normal operating costs. Additionally, these amounts can vary significantly from period to period based on current activity. The Company also excludes revenue and expense attributable to businesses held-for-sale in the calculation of our non-GAAP financial measures.

The Company's non-GAAP adjusted operating margin, adjusted EBITDA, and adjusted net earnings, in total and on a per share basis, also excludes acquisition related expenses inclusive of the changes in fair value of contingent consideration, and other non-recurring items including certain costs related to goodwill and long-lived asset impairments, and gains. We also exclude certain litigation charges which are facts and circumstances specific including costs to resolve litigation and legal settlement (gains and losses). In some cases, these costs may be a result of litigation matters at acquired companies that were not probable, inestimable, or unresolved at the time of acquisition.

The Company's non-GAAP adjusted EBITDA and adjusted net earnings, in total and on a per share basis, also excludes gains and losses from investments, as they are not part of our day-to-day operating decisions (excluding our equity method investment in Wilson Wolf as it is certain to be acquired in the future) and certain adjustments to income tax expense. Additionally, gains and losses from investments that are either isolated or cannot be expected to occur again with any predictability are excluded. The Company independently calculates a non-GAAP adjusted tax rate to be applied to the identified non-GAAP adjustments considering the impact of discrete items on these adjustments and the jurisdictional mix of the adjustments. In addition, the tax impact of other discrete and non-recurring charges which impact our reported GAAP tax rate are adjusted from net earnings. We believe these tax items can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results.

SOURCE Bio-Techne Corporation

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Jazz Pharmaceuticals (JAZZ - Free Report) and Techne (TECH - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.

Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.

Jazz Pharmaceuticals and Techne are sporting Zacks Ranks of #2 (Buy) and #4 (Sell), respectively, right now. This means that JAZZ's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is just one piece of the puzzle for value investors.

Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.

The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.

JAZZ currently has a forward P/E ratio of 10.31, while TECH has a forward P/E of 35.29. We also note that JAZZ has a PEG ratio of 0.20. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. TECH currently has a PEG ratio of 7.40.

Another notable valuation metric for JAZZ is its P/B ratio of 3.54. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, TECH has a P/B of 5.41.

Based on these metrics and many more, JAZZ holds a Value grade of B, while TECH has a Value grade of D.

JAZZ sticks out from TECH in both our Zacks Rank and Style Scores models, so value investors will likely feel that JAZZ is the better option right now.

CMB.TECH FLEET UPDATE ANTWERP, Belgium, 3 August 2026, 08:00 CET – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) has sold one VLCC, generating a capital gain of approximately 74.4 million USD. Euronav CMB.TECH has sold the VLCC Donoussa (2016, 299,999 dwt).

Posted by Defense World Staff on Jul 31st, 2026

Bank of Nova Scotia reduced its position in shares of Bio-Techne Corp (NASDAQ:TECH – Free Report) by 78.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,637 shares of the biotechnology company’s stock after selling 38,334 shares during the period. Bank of Nova Scotia’s holdings in Bio-Techne were worth $556,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. Asset Management One Co. Ltd. grew its stake in Bio-Techne by 2.7% in the fourth quarter. Asset Management One Co. Ltd. now owns 5,752 shares of the biotechnology company’s stock worth $341,000 after purchasing an additional 153 shares during the period. Accredited Investors Inc. lifted its position in Bio-Techne by 2.7% during the fourth quarter. Accredited Investors Inc. now owns 6,052 shares of the biotechnology company’s stock valued at $356,000 after buying an additional 161 shares during the period. Oppenheimer & Co. Inc. boosted its holdings in shares of Bio-Techne by 3.5% during the 4th quarter. Oppenheimer & Co. Inc. now owns 5,351 shares of the biotechnology company’s stock valued at $315,000 after buying an additional 181 shares in the last quarter. Bryn Mawr Trust Advisors LLC boosted its holdings in shares of Bio-Techne by 5.1% during the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 3,986 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 194 shares in the last quarter. Finally, New Mexico Educational Retirement Board grew its position in shares of Bio-Techne by 2.8% in the 4th quarter. New Mexico Educational Retirement Board now owns 7,300 shares of the biotechnology company’s stock worth $429,000 after buying an additional 200 shares during the period. 98.95% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth Several equities analysts have recently weighed in on TECH shares. William Blair downgraded Bio-Techne from an “outperform” rating to a “market perform” rating in a report on Thursday, June 25th. Robert W. Baird increased their price objective on shares of Bio-Techne from $49.00 to $73.00 and gave the company a “neutral” rating in a research report on Friday, June 26th. Piper Sandler assumed coverage on shares of Bio-Techne in a research note on Thursday, June 11th. They set a “neutral” rating and a $65.00 price objective for the company. Citigroup cut shares of Bio-Techne from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $70.00 to $73.00 in a report on Friday, June 26th. Finally, Evercore cut shares of Bio-Techne from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Three analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Bio-Techne currently has a consensus rating of “Hold” and an average target price of $68.08.

View Our Latest Report on Bio-Techne

Bio-Techne Price Performance NASDAQ TECH opened at $72.03 on Friday. The company has a current ratio of 4.49, a quick ratio of 3.18 and a debt-to-equity ratio of 0.10. Bio-Techne Corp has a 12 month low of $43.19 and a 12 month high of $72.36. The stock has a market cap of $11.28 billion, a price-to-earnings ratio of 104.39, a PEG ratio of 8.58 and a beta of 1.29. The company’s 50 day moving average is $62.56 and its two-hundred day moving average is $58.98.

Bio-Techne (NASDAQ:TECH – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.02). The business had revenue of $311.42 million during the quarter, compared to analysts’ expectations of $316.11 million. Bio-Techne had a return on equity of 13.57% and a net margin of 9.05%.The company’s quarterly revenue was down 1.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.56 EPS. As a group, research analysts anticipate that Bio-Techne Corp will post 1.65 earnings per share for the current year.

Bio-Techne Announces Dividend The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 29th. Shareholders of record on Monday, May 18th were given a dividend of $0.08 per share. The ex-dividend date was Monday, May 18th. This represents a $0.32 annualized dividend and a yield of 0.4%. Bio-Techne’s dividend payout ratio (DPR) is 46.38%.

About Bio-Techne (Free Report)

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.

Featured Stories Five stocks we like better than Bio-Techne Microsoft Just Flipped the AI Spending Narrative Overnight Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling? Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes

Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBank of Nova Scotia Sells 2,021,827 Shares of Guidewire Software, Inc. $GWRE

NEXT HEADLINE »Clean Harbors (NYSE:CLH) Given New $365.00 Price Target at Truist Financial

Posted by Defense World Staff on Jul 29th, 2026

Dimensional Fund Advisors LP grew its position in Bio-Techne Corp (NASDAQ:TECH – Free Report) by 10.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,973,136 shares of the biotechnology company’s stock after purchasing an additional 178,843 shares during the quarter. Dimensional Fund Advisors LP owned about 1.26% of Bio-Techne worth $103,118,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in TECH. Morgan Stanley boosted its position in shares of Bio-Techne by 15.3% in the 4th quarter. Morgan Stanley now owns 8,345,414 shares of the biotechnology company’s stock worth $490,794,000 after purchasing an additional 1,107,536 shares in the last quarter. State Street Corp boosted its holdings in Bio-Techne by 1.0% in the fourth quarter. State Street Corp now owns 5,812,032 shares of the biotechnology company’s stock worth $341,806,000 after acquiring an additional 58,639 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Bio-Techne by 12.1% in the fourth quarter. Wellington Management Group LLP now owns 5,734,049 shares of the biotechnology company’s stock worth $337,219,000 after acquiring an additional 618,916 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Bio-Techne by 21.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,075,194 shares of the biotechnology company’s stock worth $239,663,000 after acquiring an additional 725,050 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of Bio-Techne by 164.4% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,012,818 shares of the biotechnology company’s stock worth $235,994,000 after acquiring an additional 2,495,328 shares during the last quarter. 98.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth Several brokerages recently commented on TECH. Zacks Research lowered shares of Bio-Techne from a “hold” rating to a “strong sell” rating in a research report on Monday, June 8th. Weiss Ratings upgraded shares of Bio-Techne from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, May 7th. Wells Fargo & Company decreased their price target on shares of Bio-Techne from $76.00 to $62.00 and set an “overweight” rating for the company in a report on Thursday, May 7th. Royal Bank Of Canada downgraded shares of Bio-Techne from an “outperform” rating to a “sector perform” rating and lifted their price objective for the stock from $62.00 to $73.00 in a research note on Thursday, July 9th. Finally, Robert W. Baird boosted their price objective on shares of Bio-Techne from $49.00 to $73.00 and gave the company a “neutral” rating in a report on Friday, June 26th. Three research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $68.08.

Read Our Latest Report on Bio-Techne

Bio-Techne Stock Performance Shares of NASDAQ TECH opened at $72.07 on Wednesday. The company has a current ratio of 4.49, a quick ratio of 3.18 and a debt-to-equity ratio of 0.10. Bio-Techne Corp has a 12 month low of $43.19 and a 12 month high of $72.16. The company has a 50 day simple moving average of $61.56 and a two-hundred day simple moving average of $58.89. The stock has a market cap of $11.28 billion, a price-to-earnings ratio of 104.45, a PEG ratio of 8.53 and a beta of 1.29.

Bio-Techne (NASDAQ:TECH – Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.53 earnings per share for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.02). Bio-Techne had a net margin of 9.05% and a return on equity of 13.57%. The company had revenue of $311.42 million for the quarter, compared to analysts’ expectations of $316.11 million. During the same quarter in the previous year, the business posted $0.56 EPS. The business’s quarterly revenue was down 1.5% on a year-over-year basis. As a group, analysts predict that Bio-Techne Corp will post 1.65 earnings per share for the current year.

Bio-Techne Announces Dividend The business also recently declared a quarterly dividend, which was paid on Friday, May 29th. Shareholders of record on Monday, May 18th were issued a $0.08 dividend. The ex-dividend date of this dividend was Monday, May 18th. This represents a $0.32 dividend on an annualized basis and a yield of 0.4%. Bio-Techne’s payout ratio is presently 46.38%.

Bio-Techne Company Profile (Free Report)

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.

See Also Five stocks we like better than Bio-Techne These 3 Stocks Have Soared in 2026—Can They Keep Climbing? Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction Chips & Clips: Memory Tariffs Rewire Tech Supply Chains Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne Corp (NASDAQ:TECH – Free Report).

Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEEntegris, Inc. $ENTG Shares Sold by Dimensional Fund Advisors LP

NEXT HEADLINE »Dimensional Fund Advisors LP Raises Stock Holdings in Lumen Technologies, Inc. $LUMN

Posted by Defense World Staff on Jul 28th, 2026

American Capital Management Inc. increased its position in shares of Bio-Techne Corp (NASDAQ:TECH – Free Report) by 8.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,021,128 shares of the biotechnology company’s stock after purchasing an additional 79,979 shares during the quarter. Bio-Techne makes up about 2.9% of American Capital Management Inc.’s holdings, making the stock its 11th biggest position. American Capital Management Inc. owned approximately 0.65% of Bio-Techne worth $53,364,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Danske Bank A S purchased a new stake in Bio-Techne during the fourth quarter valued at about $29,000. eCIO Inc. purchased a new stake in shares of Bio-Techne during the 4th quarter valued at approximately $30,000. Measured Wealth Private Client Group LLC bought a new position in Bio-Techne in the 3rd quarter worth approximately $32,000. iSAM Funds UK Ltd bought a new position in Bio-Techne in the 3rd quarter worth approximately $33,000. Finally, EverSource Wealth Advisors LLC grew its stake in Bio-Techne by 506.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 673 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 562 shares in the last quarter. 98.95% of the stock is owned by institutional investors.

Bio-Techne Stock Performance NASDAQ:TECH opened at $71.62 on Tuesday. The business has a 50 day moving average of $61.03 and a 200 day moving average of $58.84. The company has a market capitalization of $11.21 billion, a price-to-earnings ratio of 103.80, a PEG ratio of 8.53 and a beta of 1.29. Bio-Techne Corp has a 1-year low of $43.19 and a 1-year high of $72.16. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.49 and a quick ratio of 3.18.

Bio-Techne (NASDAQ:TECH – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.55 by ($0.02). Bio-Techne had a net margin of 9.05% and a return on equity of 13.57%. The business had revenue of $311.42 million for the quarter, compared to analysts’ expectations of $316.11 million. During the same quarter in the previous year, the company earned $0.56 earnings per share. The business’s quarterly revenue was down 1.5% on a year-over-year basis. On average, sell-side analysts predict that Bio-Techne Corp will post 1.65 earnings per share for the current fiscal year.

Bio-Techne Dividend Announcement The business also recently disclosed a quarterly dividend, which was paid on Friday, May 29th. Shareholders of record on Monday, May 18th were issued a $0.08 dividend. The ex-dividend date was Monday, May 18th. This represents a $0.32 annualized dividend and a yield of 0.4%. Bio-Techne’s dividend payout ratio is 46.38%.

Wall Street Analysts Forecast Growth Several equities research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft downgraded Bio-Techne from a “buy” rating to a “hold” rating and set a $73.00 target price on the stock. in a research report on Friday, June 26th. TD Cowen lowered Bio-Techne from a “buy” rating to a “hold” rating and boosted their price objective for the company from $65.00 to $73.00 in a research note on Monday, June 29th. Stifel Nicolaus set a $50.00 price objective on Bio-Techne in a research note on Thursday, May 7th. Zacks Research cut Bio-Techne from a “hold” rating to a “strong sell” rating in a report on Monday, June 8th. Finally, Robert W. Baird raised their target price on Bio-Techne from $49.00 to $73.00 and gave the stock a “neutral” rating in a research note on Friday, June 26th. Three equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $68.08.

Read Our Latest Stock Analysis on Bio-Techne

Bio-Techne Company Profile (Free Report)

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.

Recommended Stories Five stocks we like better than Bio-Techne AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There? Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne Corp (NASDAQ:TECH – Free Report).

Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEFerguson plc $FERG Shares Sold by Bank of Nova Scotia

NEXT HEADLINE »1ST Source Bank Sells 7,271 Shares of Amazon.com, Inc. $AMZN

Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows

New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&D Systems™ AI-Engineered Designer Protein portfolio AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing , /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&D Systems™ AI-Engineered Designer Protein portfolio, designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows.

The R&D Systems AI-Engineered Designer Protein platform enables the design and creation of new protein-based solutions to help researchers overcome current variability and scalability challenges in advanced cell culture by improving the stability and activity of critical reagents.  

By improving protein performance characteristics such as heat stability, activity, and solubility, Bio-Techne helps researchers achieve consistent results and scalable workflows from discovery through therapeutic development. These improvements are critical as cell therapies and organoid systems move toward clinical and commercial scale, where minor variations in cell signaling inputs can significantly impact outcomes.

These additions build on Bio-Techne's strategy to develop a comprehensive portfolio of next-generation signaling technologies, following an earlier expansion of the R&D Systems AI-Engineered Design Protein portfolio. Together, these innovations, including hyperactive cytokines, heat-stable growth factors, and signaling pathway agonists, support stem cell culture, organoid development, and regenerative medicine workflows by enabling more controlled, reproducible systems across the continuum from basic research through process development and scaled-up manufacturing.

Early adopters of R&D Systems AI-Engineered Designer Proteins are already seeing measurable gains in cell expansion and overall workflow performance across demanding applications:

"Many patient-derived Tumor-Infiltrating Lymphocytes (TIL) samples fail during initial outgrowth due to insufficient cell expansion," said Dr Branden Moriarity, Associate Professor in the Division of Pediatric Hematology/Oncology, University of Minnesota. "IL-2 Heat Stable Agonist Protein provides a promising proliferation advantage to TIL samples and also provides clear operational advantages that would reduce the cost of goods for TIL therapies."

This real-world feedback underscores the broader potential of the R&D Systems AI-Engineered Designer Protein platform. With its latest expansion to include additional cytokines and growth factors, the platform is designed to enable more consistent, scalable, and cost-efficient advanced cell culture workflows.

"As cell therapy advances from early research into clinical and commercial manufacturing, achieving consistency, robustness, and scalability across increasingly complex workflows is critical," said Will Geist, President of Bio-Techne's Protein Science Segment. "Our AI-Engineered Designer Proteins are designed to overcome these challenges by delivering enhanced stability, activity, and performance—enabling more reproducible results and supporting seamless scale-up from discovery through production."

The newly launched proteins include:

FGF-4 Heat Stable – Designed to support pluripotent stem cell maintenance, embryonic development research, and differentiation workflows requiring sustained growth factor activity. FGF-7 Heat Stable – Engineered to support epithelial and tissue regeneration workflows, including advanced 3D culture systems and organoid expansion that require sustained stability at elevated temperatures. FGF-8b Heat Stable – Optimized for developmental biology, organoid modeling, and regenerative medicine applications where precise morphogenic signaling is critical. IL-3 Heat Stable – Designed to support hematopoietic stem and progenitor cell expansion and differentiation across early-stage and lineage-committed cell populations requiring sustained cytokine stability in culture. IL-15 Hyperactive – Engineered to drive increased expansion of NK cells and T cells, supporting cell therapy workflows and immunotherapy research, where enhanced signaling strength and persistence are vital. The expansion of the AI-Engineered Designer Protein portfolio reinforces Bio-Techne's leadership in developing high-performance signaling molecules for advanced biological systems. These innovations support organoid culture, stem cell differentiation, and cell therapy manufacturing; areas where reproducible scale-up from discovery to production is increasingly a requirement for success.

For more information about the AI-Engineered Designer Protein portfolio, visit the R&D Systems website.

ABOUT BIO-TECHNE
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer-focused brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision-making. Bio-Techne operates in 34 locations worldwide and employs more than 3000 people. In fiscal year 2025, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.

For more information on Bio-Techne and its brands, please visit www.bio-techne.com or follow the company on social media at LinkedIn and X.

MEDIA CONTACTS:
Corporate Communications
[email protected] 

David Clair, Vice President
Investor Relations
[email protected]

SOURCE Bio-Techne Corporation

MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck.

Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.

Bio-Techne shareholders will receive $73 per share in cash, representing a total enterprise value of approximately $11.3 billion. Bio-Techne insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Bio-Techne by imposing a significant penalty if Bio-Techne accepts a competing bid. We are investigating the conduct of the Bio-Techne board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Bio-Techne Corporation (NasdaqGS: TECH) to Merck KGaA. Under the terms of the proposed transaction, shareholders of Bio-Techne will receive $73.00 in cash for each share of Bio-Techne that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.

, /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Bio-Techne Corporation (NASDAQ: TECH) related to its sale to Merck KGaA. Under the terms of the proposed transaction, Bio-Techne shareholders are expected to receive $73.00 per share in cash. Is it a fair deal?

Click here for more info https://monteverdelaw.com/case/bio-techne-corporation/. It is free and there is no cost or obligation to you.

NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask:

Do you file class actions and go to Court? When was the last time you recovered money for shareholders? What cases did you recover money in and how much? About Monteverde & Associates PC

Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. 

No one is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

SOURCE Monteverde & Associates PC

Today's Change

(

20.09

%) $

11.82

Current Price

$

70.70

Bio-Techne (TECH +20.09%), a life science reagents, instruments, and bioprocessing tools provider, closed at $70.67, up 20.02%. Merck KGaA’s $73-per-share cash offer drove the move, and investors are watching the deal timetable and any updates on closing conditions. Trading volume reached 51.3M shares, coming in about 1,378% above its three-month average of 3.5M shares.

How the markets moved todayThe S&P 500 (^GSPC 0.01%) finished at 7,357, down 0.01%, while the Nasdaq Composite (^IXIC 0.46%) closed at 25,359, down 0.46%. Among life sciences tools, reagents, instruments, and diagnostics/bioprocessing services peers, Danaher closed at $193.23, up 2.31%, and Repligen closed at $145.23, up 4.93%.

What this means for investorsOne week after it was reported that activist investor Ananym Capital Management had built a stake in Bio-Techne and announced it would be pushing for the company to be sold, a $73-per-share deal from Merck KGaA came in, sending shares soaring. With TECH stock now near $71, it seems the market is optimistic the deal will go through, at a time when $419 billion in healthcare deals have already been completed in 2026 -- the most since 2021.

Profitable and growing sales by 10% annually over the last decade, Bio-Techne will help reload Merck KGaA’s pipeline, adding “complementary strengths across research, bioprocessing, and advanced therapeutics.” The $70 billion acquirer believes it will achieve annualized cost synergies of over $150 million within three years, adding roughly 5% to its bottom line, based on last year’s net income of roughly $3 billion.

Josh Kohn-Lindquist has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Danaher. The Motley Fool recommends Repligen. The Motley Fool has a disclosure policy.

Bio-Techne shareholders will receive $73 per share in cash, representing a 36% premium to the company’s one-month volume-weighted average trading price.

The deal has already been approved by Bio-Techne’s board and the relevant corporate bodies of Merck KGaA and is expected to close in late 2026 or early 2027, pending shareholder and regulatory approvals.

Expanding Life Science Capabilities Across Key Growth AreasMerck KGaA said the acquisition aligns with its medium- and long-term strategy focused on high-growth areas, integrated workflows, and innovation through mergers and acquisitions.

The combination would unite two life sciences companies with complementary portfolios spanning discovery, translational research, development, testing, and commercial manufacturing.

Bio-Techne brings a broad portfolio of recombinant proteins, cytokines, growth factors, antibodies, and immunoassay kits. The company also owns ProteinSimple, which specializes in automated protein detection and analysis instruments.

Additionally, Bio-Techne’s RNAscope and related in situ hybridization technologies are expected to strengthen Merck KGaA’s capabilities in spatial biology and diagnostics.

Cell And Gene Therapy Portfolio Set To Gain ScaleThe acquisition is also expected to enhance Merck KGaA’s position in cell and gene therapy. Bio-Techne currently holds a 19.9% stake in Wilson Wolf Corporation, a manufacturer of cell culture devices, including the G-Rex product line, and expects to acquire the remaining ownership after 2027 under an existing forward contract.

Bio-Techne generated more than $1.2 billion in fiscal 2025 net sales. The company employs more than 3,000 people globally and operates 34 locations and 15 manufacturing facilities across the U.S., Canada, the U.K., Switzerland, and China.

Merck Expects Synergies And Earnings BenefitsMerck KGaA said the transaction will broaden its Process Solutions business by increasing exposure to higher-value reagents, analytics, and advanced research tools while strengthening discovery, development, and manufacturing capabilities.

The acquisition will be financed through a combination of existing cash and new debt, while the company expects to maintain an investment-grade credit rating.

Merck KGaA has cash and cash equivalents of about 2.74 billion euros ($3.11 billion), according to its latest quarterly results. 

Merck KGaA expects the transaction to be immediately accretive to EBITDA pre margin for both its Life Science business and the broader group after closing.

Earnings per share are projected to become accretive by the third year following completion, with annual cost synergies of about 140 million euros ($159.03 million) expected to be fully realized by that time.

TECH Stock Price Activity: Bio-Techne shares were up 19.39% at $70.29 during premarket trading on Thursday, according to Benzinga Pro data.

Photo: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Bio-Techne Corporation (NASDAQ: TECH) to Merck KGaA for $73.00 per share in cash. Halper Sadeh encourages Bio-Techne shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Bio-Techne and its board of directors violat.

A cyclist drives past a logo of drugs and chemicals group Merck KGaA in Darmstadt, Germany January 28, 2016. REUTERS/Ralph Orlowski/File Photo Purchase Licensing Rights, opens new tab

CompaniesJune 25 (Reuters) - German drugmaker Merck KGaA (MRCG.DE), opens new tab said on Thursday it will acquire U.S. biotech ​firm Bio-Techne Corp (TECH.O), opens new tab for $11.3 billion, expanding its presence ‌in the life sciences market.

Shares of Bio-Techne rose 22% in premarket trading following Merck's offer of $73 per share, which implies a 24% ​premium to Bio-Techne's close on Wednesday.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

With this deal, Merck ​will gain access to Bio-Techne's expertise and supplies ⁠of research reagents, proteins, antibodies, analytical instruments and other ​tools that are used by scientists and drug developers.

The deal ​follows a series of large healthcare transactions this year, including Danaher's (DHR.N), opens new tab $9.9 billion acquisition of patient-monitoring company Masimo in February, as medical technology and life ​sciences firms seek to broaden their product offerings and ​gain market share across multiple segments.

The Bio-Techne acquisition is Merck's largest life ‌sciences ⁠deal since its $17 billion takeover of Sigma-Aldrich in 2014, which bolstered the German group's laboratory supplies and research tools business and accelerated its diversification beyond pharmaceuticals.

The German firm said ​it would fund ​the Bio-Techne ⁠acquisition through a combination of cash and debt. The company has cash and cash equivalents ​of about 2.74 billion euros, according to its ​latest ⁠quarterly results.

The deal is expected to close by late 2026 or early 2027. Merck expects cost savings of about 140 ⁠million ​euros to be fully realized by ​the third year after the deal is closed.

Reporting by Danny Callaghan, Christy Santhosh ​and Padmanabhan Ananthan; Editing by Linda Pasquini and Shinjini Ganguli

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Bio-Techne stock jumps, with Germany's Merck KGaA buying the company at a 24% premium.

The Lanier Law Firm attorney Mark Lanier discusses Roblox's new safety measures, online child protection and Florida's lawsuit against TikTok on ‘Varney & Co.' #foxbusiness #varneyandco 00:00 — Mark Lanier Says Roblox Safeguards Don't Go Far Enough 01:00 — Parents, Phones, and the Growing Child Safety Challenge 01:42 — Florida Targets TikTok Over Child Safety Concerns 03:06 — States Escalate Legal Pressure on OpenAI and Big Tech 04:00 — AI Safety, Minors, and the Future of Tech Regulation

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Biogen Inc. (BIIB) and Techne (TECH). But which of these two stocks is more attractive to value investors?